 |
市场调查报告书
商品编码
1684656
非类固醇抗发炎药 (NSAID) 市场机会、成长动力、产业趋势分析与预测 2025 - 2034Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
||||||
2024 年全球非类固醇抗发炎药市场价值 223 亿美元，预计 2025 年至 2034 年期间复合年增长率将达到 5.8%。他们透过抑制产生疼痛前列腺素的环氧合酶 (COX) 来实现这一点。这些药物的需求上升主要是由于慢性疼痛疾病的盛行率不断上升，包括关节炎、肌肉骨骼疾病和背痛，这些疾病都需要持续治疗。随着全球人口不断老化，对非类固醇抗发炎药的需求变得更加明显。老年人更容易患炎症，这种人口结构的变化预计将进一步推动市场成长。
近年来，市场日益青睐那些既有效又不伤胃的药物。选择性 COX-2 抑制剂预计将成为 NSAID 市场中成长最快的领域，到 2034 年的复合年增长率预计为 5.9%。这使得选择性 COX-2 抑制剂成为长期疼痛管理的首选，尤其是对于患有骨关节炎和类风湿性关节炎等慢性疾病的患者。
| 市场范围 | |
|---|---|
| 起始年份 | 2024 |
| 预测年份 | 2025-2034 |
| 起始值 | 223亿美元 |
| 预测值 | 392亿美元 |
| 复合年增长率 | 5.8％ |
从给药途径来看，口服药物占据最大的市场份额，到 2024 年将达到 58.2%。它们为患者和医疗保健提供者提供了便利，特别是在用于需要每日服药的情况时。
预计到 2034 年，美国 NSAID 市场规模将达到 143 亿美元。因此，美国将在全球 NSAID 市场扩张中发挥关键作用。随着对有效抗发炎治疗的需求不断增加，这将为药物配方的进一步创新打开大门。
总之，受人口结构变化、慢性疼痛盛行率上升以及药物开发技术进步等因素的推动，NSAID 市场将实现稳定、持续的成长。无论是透过新配方还是改进的给药方法，NSAID 治疗的创新机会将继续塑造市场的未来。
目录
第 1 章：方法论与范围
第 2 章：执行摘要
第 3 章：产业洞察
- 产业生态系统分析
- 产业衝击力
- 成长动力
- 慢性疼痛和发炎性疾病盛行率上升
- 药物输送系统的技术进步
- 对非处方非类固醇抗发炎药的认知度和可及性
- 产业陷阱与挑战
- 副作用和安全问题
- 严格的监管环境
- 成长动力
- 成长潜力分析
- 监管格局
- 差距分析
- 管道分析
- 波特的分析
- PESTEL 分析
第四章：竞争格局
- 介绍
- 公司市占率分析
- 公司矩阵分析
- 主要市场参与者的竞争分析
- 竞争定位矩阵
- 策略仪表板
第 5 章：市场估计与预测：按药物类别，2021 年至 2034 年
- 主要趋势
- 选择性 COX-2 抑制剂
- 非选择性 COX 抑制剂
第 6 章：市场估计与预测：按管理路线，2021 年至 2034 年
- 主要趋势
- 口服
- 肠外
- 主题
第 7 章：市场估计与预测：按应用，2021 年至 2034 年
- 主要趋势
- 关节炎
- 偏头痛
- 眼科疾病
- 其他应用
第 8 章：市场估计与预测：按配销通路，2021 年至 2034 年
- 主要趋势
- 医院药房
- 零售药局
- 网路药局
第 9 章：市场估计与预测：按地区，2021 年至 2034 年
- 主要趋势
- 北美洲
- 我们
- 加拿大
- 欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
第十章：公司简介
- Abbott Laboratories
- Bayer AG
- Cipla
- Dr. Reddy's Laboratories
- Glenmark Pharmaceuticals
- Hikma Pharmaceuticals
- Johnson & Johnson
- Lupin
- Novartis
- Pfizer
- Sun Pharmaceutical Industries
- Teva Pharmaceuticals
- Torrent Pharmaceuticals
- Viatris
- Zydus Healthcare
The Global Non-Steroidal Anti-Inflammatory Drugs Market was valued at USD 22.3 billion in 2024, with expectations to expand at a robust CAGR of 5.8% from 2025 to 2034. NSAIDs are widely recognized for their effectiveness in reducing inflammation, alleviating pain, and controlling fever. They achieve this by inhibiting cyclooxygenase (COX) enzymes that produce pain-causing prostaglandins. The rise in demand for these drugs is largely driven by the increasing prevalence of chronic pain conditions, including arthritis, musculoskeletal disorders, and back pain, all of which require ongoing management. As the global population continues to age, the need for NSAIDs becomes even more significant. Older adults are more susceptible to inflammatory conditions, and this demographic shift is expected to further fuel market growth.
In recent years, the market has seen an increasing shift toward drugs that are both effective and easier on the stomach. Selective COX-2 inhibitors are predicted to be the fastest-growing segment within the NSAID market, with a projected CAGR of 5.9% through 2034. These drugs target the COX-2 enzyme, which is primarily responsible for inflammation and pain while minimizing the gastrointestinal issues commonly seen with non-selective COX inhibitors. This makes selective COX-2 inhibitors a preferred choice for long-term pain management, especially in patients suffering from chronic conditions such as osteoarthritis and rheumatoid arthritis.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $22.3 Billion |
| Forecast Value | $39.2 Billion |
| CAGR | 5.8% |
Looking at the route of administration, the oral segment holds the largest market share, capturing 58.2% in 2024. Oral NSAIDs are favored for their ease of use, cost-effectiveness, and wide availability, making them the go-to solution for managing both acute and chronic pain. They offer convenience for patients and healthcare providers, particularly when used for conditions that require daily medication.
The U.S. market for NSAIDs is expected to reach USD 14.3 billion by 2034. This growth is driven by the aging population, which is rapidly increasing and creating a growing demand for treatments for age-related inflammatory diseases. As a result, the U.S. is set to play a pivotal role in the expansion of the global NSAID market. As the need for effective anti-inflammatory treatments continues to rise, this will open doors for further innovations in drug formulations.
In conclusion, the NSAID market is set for steady and sustained growth, fueled by a combination of demographic shifts, the increasing prevalence of chronic pain, and technological advancements in drug development. Whether through new formulations or improved delivery methods, opportunities for innovation in NSAID treatments will continue to shape the market's future.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of chronic pain and inflammatory diseases
- 3.2.1.2 Technological advancement in drug delivery systems
- 3.2.1.3 Awareness and accessibility of OTC NSAIDs
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 Side effects and safety concerns
- 3.2.2.2 Stringent regulatory scenario
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Gap analysis
- 3.6 Pipeline analysis
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)
- 5.1 Key trends
- 5.2 Selective COX-2 inhibitors
- 5.3 Non-selective COX inhibitors
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)
- 6.1 Key trends
- 6.2 Oral
- 6.3 Parenteral
- 6.4 Topical
Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)
- 7.1 Key trends
- 7.2 Arthritis
- 7.3 Migraine
- 7.4 Ophthalmic diseases
- 7.5 Other applications
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Retail pharmacies
- 8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 India
- 9.4.3 Japan
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
Chapter 10 Company Profiles
- 10.1 Abbott Laboratories
- 10.2 Bayer AG
- 10.3 Cipla
- 10.4 Dr. Reddy’s Laboratories
- 10.5 Glenmark Pharmaceuticals
- 10.6 Hikma Pharmaceuticals
- 10.7 Johnson & Johnson
- 10.8 Lupin
- 10.9 Novartis
- 10.10 Pfizer
- 10.11 Sun Pharmaceutical Industries
- 10.12 Teva Pharmaceuticals
- 10.13 Torrent Pharmaceuticals
- 10.14 Viatris
- 10.15 Zydus Healthcare
